Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Article

    Abatacept in psoriatic arthritis: Case report and short review

    Francesco Ursini1★, Saverio Naty1, Emilio Russo2, Rosa Daniela Grembiale1★ Corresponding author

    1. 1Rheumatology Research Unit, Department of Medical and Surgical Sciences, University of Catanzaro “Magna Græcia”, Viale Europa, Catanzaro, Italy.
    2. 2Department of Health Science, School of Medicine, University of Catanzaro “Magna Græcia”, Viale Europa, Catanzaro, Italy.

    CORRESPONDENCE

    Francesco Ursini

    Rheumatology Research Unit, Department of Medical and Surgical Sciences, University of Catanzaro “Magna Græcia”, Viale Europa, Catanzaro, Italy.

    francesco.ursini@yahoo.it

    Volume 4, Issue 4S · pp. S29–S30 · PUBLISHED 2013 · DOI: 10.4103/0976-500X.120943

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting about 6-10% of patients with cutaneous psoriasis. According to current knowledge, activated T-cells seem to play a pivotal role in the pathogenesis of both psoriasis and PsA. Abatacept is a novel biologic agent selectively designed to interfere with T-cells co-stimulation. Structurally, it is a soluble, fully human fusion protein consisting of the extracellular domain of CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) linked to a modified Fc portion of human IgG1. Abatacept is now approved as a first-line treatment for rheumatoid arthritis (RA), but preliminary data disclose a potential role of abatacept in the treatment of other autoimmune diseases. In this article, we report a case of successful treatment with abatacept of a psoriatic arthritis patients who developed adverse drug reactions (ADRs) to medication commonly used in PsA, including three different anti-TNF-α agents. In addition, we review the scientific evidences supporting a possible role of abatacept in treatment of patients with psoriasis and PsA and the paradox of abatacept-induced psoriasis.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Ursini, F., Naty, S., Russo, E., & Grembiale, R. D. (2013). Abatacept in psoriatic arthritis: Case report and short review. Journal of Pharmacology and Pharmacotherapeutics, 4(4S), S29–S30. https://doi.org/10.4103/0976-500X.120943